Customised Services in Preclinical Inflammation

About Redoxis

We contribute with knowledge and competence

Redoxis is a CRO with core expertise and focus on preclinical drug development and efficacy evaluation in models of autoimmune disease. With the roots in academic research we are continuously updating our portfolio of models and are connected to the latest immunology research. We take great pride in personal communication and commitment in our studies – for the benefit of your preclinical project! 

Pipett with blue fluid


Your personal CRO

Redoxis is a Swedish CRO with a core competence and experience in preclinical models for autoimmune and inflammatory conditions. We provide a wide range of in vivo and in vitro models validated with standard reference therapies. These models are excellent tools for investigation of therapeutic efficacy and MoA of novel therapies.

Redoxis performs tailor-made preclinical studies combining dedication, experience and agility to provide reliable results to your project.

Please contact us for an overview of our services, advice on model selection or study setup and quotes.

Person holding glass with red fluid

Redoxis and Amarna Therapeutics receive EUREKA Eurostars grant for project ALPHAVAC

We are happy to announce that Redoxis, together with our Dutch partner Amarna Therapeutics has been awarded a €0,8 million grant from EUREKA Eurostars to establish a screening platform for the advancement of potential first-in-class gene therapy for ALS and other neurodegenerative diseases using Amarna´s proprietary SVec viral vector platform.

See post See all posts
Working together in lab